Mapping Technology Drives Quick Turn-Around on Pending Bird Flu Treatment; Consortium of Universities, Government Agencies and Biotech Labs Use Mindjet MindManager to Develop Nano-Scale Countermeasure to Deadly Virus

Business Wire, March 8, 2006

WASHINGTON -- Mindjet Corporation, the leading provider of software for visualizing and managing information, and the Advanced Medical Countermeasures Consortium announced yesterday at FOSE (www.fose.com) that drug trials will begin in late April to test the first single "therapeutic multi-threat countermeasure" for treating patients exposed to avian flu H5N1. The NIH-funded trials will test a new approach using specially designed liposomes, nanotechnology-sized syringes filled with drugs designed to stop the deadly inflammation that accompanies the virus. The drug treatment, known as STIMAL, would ideally be administered as part of a "cocktail" along a viracidal drug such as Tamiflu(R). This breakthrough approach was developed using Mindjet(R) MindManager(R) to create visual "mind maps" of complex research approaches, organization and data.

"Much of the research into bird flu treatment has been directed at neutralizing the virus itself," said Dr. Milton Smith, president of Amaox, Ltd., the biotech firm leading the project. "We have taken an entirely different approach, looking instead at the chief causes of mortality from the virus; inflammation and the ability of the virus to use the inflammatory response to accelerate replication. This new approach grew out of and has been accelerated by our ability to visually aggregate and interact with research information being generated at six different universities' labs."

The multi-threat countermeasure therapy was developed by the Advanced Medical Countermeasures Consortium, made up of researchers at the U.S. Army Medical Research Institute for Chemical Defense, Harvard Medical School, Meharry Medical College, University of Michigan, East Tennessee State University, Drexel University, Northern Ontario Medical School, AFG Biosolutions, and Amaox, Ltd.

The STIMAL treatment is applicable for "multi-threats" including anthrax and mustard gas. Trials for use against these biological and chemical weapons of mass destruction are already underway, funded by the Department of Defense. Currently there is no effective treatment to stabilize patients following exposure to any of these threats. Lacking such treatment, serious illness and death from inflammation can occur during the 24 to 48 hours needed to identify the toxin used. The STIMAL therapeutic multi-threat countermeasure would allow emergency response teams to immediately begin treating all patients -- even if the exact nature of the exposure was unknown.

"One of the key challenges faced by both government and businesses is to bring information together from a wide range of sources, quickly organize that information, synthesize it to form new knowledge -- and then act on that knowledge," said Mindjet CEO Robert Gordon. "We are proud of the role MindManager is playing in this critical research that may give public health officials an important new tool in the fight against global disease and terrorism."

About Mindjet

Mindjet Corporation, the leading provider of software for visualizing and managing information, provides applications for business teams to think together, plan together, and work together. Mindjet MindManager, the company's award-winning flagship product with 750,000 licenses sold worldwide, is productivity software designed for business professionals working as individuals or in teams at Global 2000 companies. With headquarters in California and operations throughout the world, Mindjet is backed by leading international venture capital firms Investors Growth Capital and 3i. More information is available by calling toll-free 1 (877) MINDJET or by visiting http://www.mindjet.com.